Choose HA†
Prescribing Information   |  OAKneePainRelief.com
Durolane_header_large_3800x1715-1

Choose DUROLANE when life won’t wait

  • A single doctor visit.
  • One powerful injection.
  • Up to 26 weeks of pain relief with a treatment designed to increase residence time in the knee joint.‡24,32

‡The clinical relevance of this information has not been determined.

Find a Physician

DUROLANE is a single-injection hyaluronic acid treatment for knee osteoarthritis

  • Longer lasting than Synvisc-One® and than steroids.‡11,25,33
  • Chosen by more than a million doctors and patients worldwide, DUROLANE is a single-injection hyaluronic acid treatment that’s been clinically proven to match the power of 5-injection therapies for pain relief, while significantly improving the quality of life for knee osteoarthritis patients as early as 2 weeks after injection.13,20,24

Learn how DUROLANE can help

‡Some patients were treated with a three-injection Synvisc® regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.

Get your DUROLANE rebate today Get Rebate

 

DUROLANE Packaging

Patient Testimonials

Durolane_middlesection_2880x1400

Choosing DUROLANE means less time seeking pain relief and more time doing what you love.

DUROLANE FAQs

Sign up for KneeMail

Sign up

Enjoy free resources and information about OA knee pain to help you get relief and resume your active life

DUROLANE, GELSYN-3 and SUPARTZ FX are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g., acetaminophen. Risks include general knee pain and pain at the injection site.

View Use and Important Safety Information at: DUROLANE.com, GELSYN3.com, and SUPARTZFX.COM

Summary of Indications for Use:
DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.